Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078797 | 1.00 | DNM1 (0.46) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL20033712 | 0.98 | DNM1 (0.50) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL13452893 | 0.92 | DNM1 (0.36) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL2966460 | 0.92 | DNM1 (0.36) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL12710563 | 0.87 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL11852249 | 0.86 | DNM1 (0.40) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL24093996 | 0.83 | DNM1 (0.44) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL26558253 | 0.83 | DNM1 (0.44) | DNM1CA12CA1CA2CA9 | |
| SCHEMBL2964347 | 0.81 | — | — | |
| SCHEMBL13452815 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | DNM1 3029/4885CA12 3156/4885CA1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.